ArticleInternational journal of molecular sciences2026
Genome-Wide Characterisation of Somatic Mutations Across COSMIC Cancer Cell Lines Enables Gene-Centric Experimental Model Selection.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Cancer cell lines are widely used to investigate cancer-associated mutations and evaluate candidate therapeutic compounds, but selecting an appropriate model carrying a specific mutation can be challenging. A genome-wide analysis of somatic mutations across 1020 human cancer cell lines from the COSMIC Cell Lines Project was performed to establish a gene- and variant-centric approach for experimental model selection. Transcript-specific annotations were normalised to gene symbols, and redundant transcript-derived records were removed. The resulting dataset contained 3,937,879 unique somatic mutation events affecting 18,885 genes, including 95,307 mutation events across 579 Cancer Gene Census Tier 1 genes. Substantial variation in mutation burden was observed among cell lines, while recurrent cancer-associated genes, including
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.